Bartholomeus Jf Van Den Bemt

List of Publications by Year
in descending order

123 papers	3,298 citations	172457 29 h-index	189892 50 g-index
125 all docs	125 docs citations	125 times ranked	4034 citing authors

#	Article	IF	Citations
1	Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Review of Clinical Immunology, 2012, 8, 337-351.	3.0	240
2	Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis and Rheumatology, 2018, 70, 60-68.	5.6	142
3	Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ, The, 2015, 350, h1389-h1389.	6.0	135
4	Prevalence and Preventability of Drug-Related Hospital Readmissions: A Systematic Review. Journal of the American Geriatrics Society, 2018, 66, 602-608.	2.6	135
5	Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs. Journal of Rheumatology, 2009, 36, 2164-2170.	2.0	120
6	Patient-centred care in established rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2015, 29, 643-663.	3.3	99
7	Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar <scp>SB</scp>4. Arthritis and Rheumatology, 2018, 70, 1408-1418.	5.6	90
8	Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1849-1854.	0.9	88
9	Identifying the Optimal Role for Pharmacists in Care Transitions: A Systematic Review. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 614-638.	0.9	84
10	The accuracy, precision and sustainability of different techniques for tablet subdivision: Breaking by hand and the use of tablet splitters or a kitchen knife. International Journal of Pharmaceutics, 2014, 466, 44-51.	5.2	73
11	Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. The Cochrane Library, 2014, , CD010455.	2.8	61
12	A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Delivery, 2019, 26, 384-392.	5.7	60
13	Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Research and Therapy, 2015, 17, 281.	3.5	58
14	Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: A randomized controlled trial. Patient Education and Counseling, 2014, 94, 356-361.	2.2	55
15	The effect of electronic monitoring feedback on medication adherence and clinical outcomes: A systematic review. PLoS ONE, 2017, 12, e0185453.	2.5	55
16	The effect of a pharmacy-led transitional care program on medication-related problems post-discharge: A before—After prospective study. PLoS ONE, 2019, 14, e0213593.	2.5	50
17	Effect of Interactive eHealth Interventions on Improving Medication Adherence in Adults With Long-Term Medication: Systematic Review. Journal of Medical Internet Research, 2021, 23, e18901.	4.3	50
18	Matching Adherence Interventions to Patient Determinants Using the Theoretical Domains Framework. Frontiers in Pharmacology, 2016, 7, 429.	3.5	47

#	ARTICLE	IF	CITATIONS
19	Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Annals of the Rheumatic Diseases, 2008, 67, 1697-1701.	0.9	46
20	Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis. Patient Preference and Adherence, 2014, 8, 1635.	1.8	46
21	Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases, 2016, 75, 1939-1944.	0.9	46
22	The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology, 2016, 55, 704-709.	1.9	45
23	Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology, 2010, 49, 1801-1803.	1.9	44
24	Barriers and facilitators with medication use during the transition from hospital to home: a qualitative study among patients. BMC Health Services Research, 2019, 19, 204.	2.2	41
25	Dual-tasking interferes with obstacle avoidance reactions in healthy seniors. Gait and Posture, 2012, 36, 236-240.	1.4	39
26	Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskeletal Disorders, 2013, 14, 299.	1.9	39
27	How can we improve adherence to therapy by patients with rheumatoid arthritis?. Nature Clinical Practice Rheumatology, 2007, 3, 681-681.	3.2	37
28	NSAIDs and the Risk of Accidental Falls in the Elderly. Drug Safety, 2009, 32, 489-498.	3.2	37
29	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study. BMC Musculoskeletal Disorders, 2011, 12, 12.	1.9	35
30	The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non€)response to infliximab in rheumatoid arthritis. British Journal of Clinical Pharmacology, 2013, 76, 939-945.	2.4	32
31	Pharmacists€™ Activities to Reduce Medication Waste: An International Survey. Pharmacy (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlo	1.6	32
32	Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Europace, 2019, 21, 414-420.	1.7	31
33	Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists. BMC Cancer, 2017, 17, 122.	2.6	30
34	2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. Annals of the Rheumatic Diseases, 2021, 80, 707-713.	0.9	30
35	Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?. PLoS ONE, 2017, 12, e0171070.	2.5	30
36	Making the rheumatologist aware of patients' non-adherence does not improve medication adherence in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2011, 40, 192-196.	1.1	29

#	ARTICLE	IF	CITATIONS
37	Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations. Annals of the Rheumatic Diseases, 2020, 79, 170-175.	0.9	29
38	Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. BMC Musculoskeletal Disorders, 2016, 17, 442.	1.9	28
39	Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients. Rheumatology, 2016, 55, 1812-1819.	1.9	27
40	Redispensing of medicines unused by patients: a qualitative study among stakeholders. International Journal of Clinical Pharmacy, 2017, 39, 196-204.	2.1	27
41	Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty. Acta Anaesthesiologica Scandinavica, 2017, 61, 338-345.	1.6	27
42	Medication-Related Hospital Readmissions Within 30â€‰Days of Discharge: Prevalence, Preventability, Type of Medication Errors and Risk Factors. Frontiers in Pharmacology, 2021, 12, 567424.	3.5	26
43	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskeletal Disorders, 2012, 13, 184.	1.9	25
44	Psychosocial predictors of non-adherence to chronic medication: systematic review of longitudinal studies. Patient Preference and Adherence, 2014, 8, 519.	1.8	24
45	Severity of Diabetes Mellitus and Total Hip or Knee Replacement. Medicine (United States), 2016, 95, e3739.	1.0	24
46	Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials, 2018, 19, 204.	1.6	23
47	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. RMD Open, 2020, 6, e001432.	3.8	23
48	Safety and efficacy of new oral anticoagulants and lowâ€‰molecularâ€‰weight heparins compared with aspirin in patients undergoing total knee and hip replacements. Pharmacoepidemiology and Drug Safety, 2016, 25, 1245-1252.	1.9	22
49	Willingness of patients to use unused medication returned to the pharmacy by another patient: a cross-sectional survey. BMJ Open, 2019, 9, e024767.	1.9	22
50	Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy. Research in Social and Administrative Pharmacy, 2019, 15, 100-105.	3.0	22
51	Pharmacokinetics of 450â€‰mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. British Journal of Clinical Pharmacology, 2013, 75, 1321-1327.	2.4	21
52	Interventions to support shared decision making for medication therapy in long term conditions: A systematic review. Patient Education and Counseling, 2020, 103, 254-265.	2.2	21
53	Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. Drug Safety, 2020, 43, 917-925.	3.2	20
54	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis. Patient Preference and Adherence, 2018, Volume 12, 349-358.	1.8	19

#	ARTICLE	IF	CITATIONS
55	Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. Lancet Rheumatology, The, 2019, 1, e145-e153.	3.9	19
56	Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique. Arthritis Care and Research, 2020, 72, 1410-1419.	3.4	19
57	Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: A cross-sectional study in patients with atrial fibrillation. Patient Education and Counseling, 2021, 104, 155-162.	2.2	19
58	Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in the Netherlands. Current Medical Research and Opinion, 2009, 25, 195-204.	1.9	18
59	Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case–control study. British Journal of Clinical Pharmacology, 2016, 81, 370-378.	2.4	18
60	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials, 2017, 18, 403.	1.6	18
61	Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts. Current Opinion in Rheumatology, 2018, 30, 266-275.	4.3	18
62	Unraveling the Association Between SSRI Use and Falls. Clinical Neuropharmacology, 2011, 34, 210-215.	0.7	17
63	Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis. Patient Education and Counseling, 2012, 89, 143-151.	2.2	17
64	Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 843-857.	3.3	17
65	What does it cost to redispense unused medications in the pharmacy? A micro-costing study. BMC Health Services Research, 2019, 19, 243.	2.2	17
66	Validity of a nationwide medication record system in the Netherlands. International Journal of Clinical Pharmacy, 2019, 41, 687-690.	2.1	17
67	Disentangling Rheumatoid Arthritis Patients' Implicit and Explicit Attitudes toward Methotrexate. Frontiers in Pharmacology, 2016, 7, 233.	3.5	16
68	Older Patients' Compliance with Drug Storage Recommendations. Drugs and Aging, 2018, 35, 233-241.	2.7	16
69	<p>Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment</p>. Patient Preference and Adherence, 2019, Volume 13, 1199-1211.	1.8	16
70	Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 2260-2261.	0.9	15
71	Diagnostic accuracy of a single–lead portable ECG device for measuring QTc prolongation. Annals of Noninvasive Electrocardiology, 2020, 25, e12683.	1.1	15
72	Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. Journal of Rheumatology, 2020, 47, 1565-1574.	2.0	15

#	Article	IF	Citations
73	Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. Rheumatology, 2020, 59, 1253-1261.	1.9	15
74	Economic impact of Patient's Own Medication use during hospitalisation: a multicentre pre-post implementation study. International Journal of Clinical Pharmacy, 2019, 41, 1658-1665.	2.1	12
75	A comparison between medication reconciliation by a pharmacy technician and the use of an online personal health record by patients for identifying medication discrepancies in patients' drug lists prior to elective admissions. International Journal of Medical Informatics, 2021, 147, 104370.	3.3	12
76	COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiology and Drug Safety, 2009, 18, 880-890.	1.9	11
77	Effect of Pharmacist-Led Interventions on (Non)Motor Symptoms, Medication-Related Problems, and Quality of Life in Parkinson Disease Patients: A Pilot Study. Clinical Neuropharmacology, 2018, 41, 14-19.	0.7	11
78	A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement and selection of attributes and levels. Patient Preference and Adherence, 2018, Volume 12, 1537-1555.	1.8	11
79	Information needs and patient perceptions of the quality of medication information available in hospitals: a mixed method study. International Journal of Clinical Pharmacy, 2020, 42, 1396-1404.	2.1	11
80	Impact of Ramadan Intermittent Fasting on the Heart Rate Variability and Cardiovascular Parameters of Patients with Controlled Hypertension. Journal of Nutrition and Metabolism, 2021, 2021, 1-10.	1.8	11
81	The effect of a non-steroidal anti-inflammatory drug on two important predictors for accidental falls: Postural balance and manual reaction time. A randomized, controlled pilot study. Human Movement Science, 2011, 30, 384-395.	1.4	10
82	Beliefs about inhaled corticosteroids: Comparison of community pharmacists, pharmacy technicians and patients with asthma. Journal of Asthma, 2016, 53, 1051-1058.	1.7	9
83	Pharmacokinetics of 400 mg Locally Infiltrated Ropivacaine After Total Knee Arthroplasty Without Perioperative Tourniquet Use. Regional Anesthesia and Pain Medicine, 2018, 43, 1.	2.3	9
84	Medication management issues identified during home medication reviews for ambulatory community pharmacy patients. Canadian Pharmacists Journal, 2019, 152, 334-342.	0.8	9
85	The development of a test battery to assess the hand–eye functions relevant in predicting easy and accurate tablet subdivision in older people: A pilot study. British Journal of Clinical Pharmacology, 2020, 86, 1969-1981.	2.4	9
86	Adherence to oral anticancer agents: Healthcare providers' perceptions, beliefs and shared decision making in Belgium and the Netherlands. Acta Oncológica, 2016, 55, 437-443.	1.8	8
87	Creating an Interprofessional guideline to support patients receiving oral anticoagulation therapy: a Delphi exercise. International Journal of Clinical Pharmacy, 2019, 41, 1012-1020.	2.1	7
88	Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximab. Rheumatology, 2022, 61, 3974-3980.	1.9	7
89	The Association Between β-Blocker Use and Cardiorespiratory Fitness: The Maastricht Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 37-45.	2.0	6
90	Effect of Ramadan fasting on heart rate variability as a measure of cardiac stress in a Lebanese cohort. European Journal of Clinical Nutrition, 2020, 74, 1237-1239.	2.9	6

#	Article	IF	Citations
91	Impact of Fasting on Cardiovascular Outcomes in Patients With Hypertension. Journal of Cardiovascular Pharmacology, 2021, 78, 481-495.	1.9	6
92	<scp>CNS</scp> effects of indomethacin: should patients be cautioned about decreased mental alertness and motor coordination?. British Journal of Clinical Pharmacology, 2013, 75, 814-821.	2.4	5
93	Association between healthcare practitioners' beliefs about statins and patients' beliefs and adherence. British Journal of Clinical Pharmacology, 2021, 87, 1082-1088.	2.4	5
94	Antidrug antibodies to tumour necrosis factor specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective; comment on the article by Vincent <i>et al</i>. Annals of the Rheumatic Diseases, 2013, 72, e14-e14.	0.9	4
95	Redispensing of unused HIV post-exposure prophylaxis for medical students. Travel Medicine and Infectious Disease, 2019, 29, 82-83.	3.0	4
96	Patients' and providers' perspectives on medication relatedness and potential preventability of hospital readmissions within 30 days of discharge. Health Expectations, 2020, 23, 212-219.	2.6	4
97	Electronic Monitoring Feedback for Improving Medication Adherence and Clinical Outcomes in Early Rheumatoid Arthritis: A Randomized Clinical Trial. Patient Preference and Adherence, 2021, Volume 15, 1107-1119.	1.8	4
98	Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 1985.	2.4	4
99	Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population. British Journal of Clinical Pharmacology, 2022, , .	2.4	4
100	InforMatrixÂ®: treatment of rheumatoid arthritis using biologicals. Expert Opinion on Pharmacotherapy, 2006, 7, 1769-1789.	1.8	3
101	Are Health Care Professionals' Implicit and Explicit Attitudes Toward Conventional Diseaseâ€Modifying Antirheumatic Drugs Associated With Those of Their Patients?. Arthritis Care and Research, 2021, 73, 364-373.	3.4	3
102	The effect of a transitional pharmaceutical care program on the occurrence of ADEs after discharge from hospital in patients with polypharmacy. Research in Social and Administrative Pharmacy, 2021, 18, 2651-2651.	3.0	3
103	Rheumatologists' beliefs about medication barely differ from patients' medication beliefs. European Journal for Person Centered Healthcare, 2017, 5, 308.	0.3	3
104	Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial. RMD Open, 2022, 8, e001712.	3.8	3
105	Identification of antithrombotic drugs related to total joint replacement using anonymised free-text notes: a search strategy in the Clinical Practice Research Datalink. BMJ Open, 2015, 5, e009017.	1.9	2
106	Impact of the definition of osteoarthritis and of the timing of its onset on the association between type 2 diabetes mellitus and osteoarthritis: Clinical Practice Research Datalink. Diabetes Research and Clinical Practice, 2019, 148, 240-248.	2.8	2
107	Stakeholders' perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. Expert Opinion on Drug Safety, 2020, 19, 1521-1528.	2.4	2
108	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. Journal of Rheumatology, 2021, 48, 1388-1394.	2.0	2

#	Article	IF	Citations
109	A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping. JMIR Serious Games, 2022, 10, e31570.	3.1	2
110	Implementation of a pharmacistâ€‑led transitional pharmaceutical care programme: Process evaluation of Medication Actions to Reduce hospital admissions through a collaboration between Community and Hospital pharmacists (MARCH). Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 1049-1069.	1.5	2
111	The effect of Patientâ€™s Own Medication use on patientâ€™s self-reported medication knowledge during hospitalisation: a pre-post intervention study. BMC Health Services Research, 2022, 22, 423.	2.2	2
112	Barriers and facilitators for the usage of a personal health record for medication reconciliation: a qualitative study among patients. British Journal of Clinical Pharmacology, 2022, , .	2.4	2
113	Comment on lâ€™Ami <i>et al</i> titled â€™Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'. Annals of the Rheumatic Diseases, 2018, 77, e67-e67.	0.9	1
114	Drug utilization in the Maastricht Study. Medicine (United States), 2020, 99, e18524.	1.0	1
115	Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. Trials, 2021, 22, 406.	1.6	1
116	Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time. British Journal of Clinical Pharmacology, 2021, , .	2.4	1
117	Application of intervention mapping to develop and evaluate a pharmaceutical discharge letter to improve information transfer between hospital and community pharmacists. Research in Social and Administrative Pharmacy, 2021, , .	3.0	1
118	Authorsâ€™ response to the letter from Kalleian Eserian et al. International Journal of Pharmaceutics, 2015, 478, 682-683.	5.2	0
119	Use of parenteral glucocorticoids and the risk of new onset type 2 diabetes mellitus: A case-control study. Diabetes Research and Clinical Practice, 2018, 139, 100-106.	2.8	0
120	FRI0097â€‑RA PATIENTSâ€™ PERSPECTIVES ON BIOLOGICAL DMARD-INDUCED ADVERSE DRUG REACTIONS AND THEIR BURDEN. , 2019, , .		0
121	LB0010â€‑ULTRA-LOW DOSES OF RITUXIMAB OR RETREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL. , 2019, , .		0
122	SP0038â€‑FACTORS IMPORTANT FOR MEDICAL ADHERENCE. , 2019, , .		0
123	Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study. Journal of Rheumatology, 2021, 48, 1480-1487.	2.0	0